Web Desc
Cancer Immunotherapy: Combinations
Organizer(s): Chris Boshoff, Lieping Chen and Lisa Coussens
Date: March 23 - 27, 2018
Location: Fairmont The Queen Elizabeth, Montreal, QC, Canada
Held in honor of cancer immunotherapy research pioneers Dr. Alan Korman and Dr. Nils Lonberg, thanks to generous support from an anonymous donor.

Sponsored by BioLegend, Inc., Bristol-Myers Squibb Company, Cancer Research UK, Cell Research, Genentech, Inc., Incyte Corporation, MedImmune, Merck & Co., Inc., OncoMed Pharmaceuticals, Inc., Pfizer Inc., Regeneron Pharmaceuticals, Inc., Surface Oncology,Takeda Pharmaceutical Company Limited, TESARO, Inc. and Thermo Fisher Scientific Inc.
Summary of Meeting:
By 2025, most patients with cancer will receive immunotherapy as part of their treatment regimen. This symposium will cover the most critical topics integral to this vision: How can we integrate, sequence or combine immunotherapy with standard-of-care cytotoxic therapy, radiotherapy and targeted therapies? Which preclinical models are best predictive of combination approaches? How do we combine immune agonists as well as molecules inhibiting immune-suppressive pathways with checkpoint inhibitors? What are the rational combinations for cancer vaccines and viro-therapy? Which combinatorial approaches could prevent or treat adaptive mechanisms of resistance? Most immunotherapies are being developed in isolation, or being tested as single agents in preclinical models or in clinical studies. This conference helps to address the gaps in knowledge of how and when to combine therapies, and how to integrate immunotherapy into current standard-of-care or novel targeted therapy approaches – both preclinical and clinical. Overall, the objectives of this meeting are to: 1) Elucidate rational combinations for immunotherapy; 2) Discuss preclinical and other models to inform combinatorial approaches; 3) Understand the relevance for biomarker approaches; and 4) Provide insights into the latest preclinical and clinical data for immunotherapy combinations.
Scholarship Deadline: November 21 2017
Discounted Abstract Deadline: November 21 2017
Abstract Deadline: December 19 2017
Discounted Registration Deadline: January 16 2018
Keystone Symposia thanks our Sponsor(s) for generously supporting this meeting:
BioLegend, Inc.Bristol-Myers Squibb CompanyCancer Research UKCell ResearchGenentech, Inc.Incyte CorporationMedImmuneMerck & Co., Inc.OncoMed Pharmaceuticals, Inc.Pfizer Inc.Regeneron Pharmaceuticals, Inc.Surface OncologyTakeda Pharmaceutical Company LimitedTESARO, Inc.Thermo Fisher Scientific Inc.
We gratefully acknowledge additional support from these exhibitors at this conference:
Caprion Biosciences Inc.Immudex USA, LLC
We gratefully acknowledge additional support for this conference from:
American Association for Cancer Research (AACR)American Society of Gene & Cell Therapy (ASGCT)Avanti Polar Lipids, Inc.Bethyl Laboratories, Inc.Charles RiverEurofins Pharma Discovery ServicesInfinity Pharmaceuticals, Inc.
We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:

Genentech, Inc.

Pfizer Inc.
We gratefully acknowledge the generous grant for this conference provided by:

National Cancer Institute (NCI)
Grant No. 1 R13 CA224868-01
Funding for this conference was made possible (in part) by 1 R13 CA224868-01 from the National Institutes of Health. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.
We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:

Click here to view more of these organizations
Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:

Click here to view more of these organizations

Program

Friday, March 23 | 4:00PM - 8:00PM
Arrival and Registration
Room: Agora


Friday, March 23 | 6:00PM - 8:00PM
Welcome Mixer
Room: Agora
No registration fees are used to fund alcohol served at this function.

Saturday, March 24 | 7:30AM - 8:30AM
Breakfast
Room: Square Dorchester/Parc Mont Royal


Saturday, March 24 | 8:30AM - 10:00AM
Welcome and Keynote Session
Room: Place du Canada

Speaker 1 of 6
* Chris H. Boshoff, Pfizer Inc., USA

Saturday, March 24 | 8:30AM - 10:00AM
Welcome and Keynote Session
Room: Place du Canada

Speaker 2 of 6
* Lieping Chen, Yale University, USA

Saturday, March 24 | 8:30AM - 10:00AM
Welcome and Keynote Session
Room: Place du Canada

Speaker 3 of 6
* Lisa M. Coussens, Oregon Health & Science University, USA

Saturday, March 24 | 8:30AM - 10:00AM
Welcome and Keynote Session
Room: Place du Canada

Speaker 4 of 6
Jedd D. Wolchok, Memorial Sloan Kettering Cancer Center, USA
Immunologic Checkpoint Blockade: Exploring Combinations and Mechanisms

Saturday, March 24 | 8:30AM - 10:00AM
Welcome and Keynote Session
Room: Place du Canada

Speaker 5 of 6
Elizabeth M. Jaffee, Johns Hopkins University, USA
Combinatorial Immunotherapy Converts Pancreatic Cancers into an Immunologic Disease

Saturday, March 24 | 8:30AM - 10:00AM
Welcome and Keynote Session
Room: Place du Canada


Coffee Break

Saturday, March 24 | 10:20AM - 12:00PM
Rational Immunotherapy Combinations: Preclinical Models as P
redictive or Responses

Room: Place du Canada

Speaker 1 of 5
* Judith A. Varner, University of California, San Diego, USA

Saturday, March 24 | 10:20AM - 12:00PM
Rational Immunotherapy Combinations: Preclinical Models as P
redictive or Responses

Room: Place du Canada

Speaker 2 of 5
Lieping Chen, Yale University, USA
Design of Combination Therapy-Based Adaptive Resistance Mechanisms in Tumor Microenvironment

Saturday, March 24 | 10:20AM - 12:00PM
Rational Immunotherapy Combinations: Preclinical Models as P
redictive or Responses

Room: Place du Canada

Speaker 3 of 5
Michele W. Teng, QIMR Berghofer Medical Research Institute, Australia
Dissecting the Immunological Mechanisms underlying the Efficacy of Neoadjuvant Immunotherapy

Saturday, March 24 | 10:20AM - 12:00PM
Rational Immunotherapy Combinations: Preclinical Models as P
redictive or Responses

Room: Place du Canada

Speaker 4 of 5
Simone A. Minnie, QIMR Berghofer Medical Research Institute, Australia
Short Talk: Stem Cell Transplantation Establishes T Cell-Dependent Myeloma Immune-Equilibrium that Can Be Enhanced with Immunotherapy

Saturday, March 24 | 10:20AM - 12:00PM
Rational Immunotherapy Combinations: Preclinical Models as P
redictive or Responses

Room: Place du Canada

Speaker 5 of 5
Hyejin Choi, Memorial Sloan Kettering Cancer Center, USA
Short Talk: Optimizing Targeted Therapy and Immune Checkpoint Blockade Therapy in Kras Mutant Lung Cancer

Saturday, March 24 | 12:00PM - 5:00PM
On Own for Lunch


Saturday, March 24 | 12:00PM - 1:00PM
Poster Setup
Room: Square Dorchester/Parc Mont Royal


Saturday, March 24 | 1:00PM - 10:00PM
Poster Viewing
Room: Square Dorchester/Parc Mont Royal


Saturday, March 24 | 2:30PM - 4:30PM
Workshop: Novel and Sequencing Approaches
Room: Place du Canada

Speaker 1 of 7
* Chris H. Boshoff, Pfizer Inc., USA

Saturday, March 24 | 2:30PM - 4:30PM
Workshop: Novel and Sequencing Approaches
Room: Place du Canada

Speaker 2 of 7
Bradley N. Mills, University of Rochester, USA
Development of a New Strategy to Treat Locally Advanced Pancreatic Cancer

Saturday, March 24 | 2:30PM - 4:30PM
Workshop: Novel and Sequencing Approaches
Room: Place du Canada

Speaker 3 of 7
Adrienne Rothschilds, Flagship Pioneering, USA
Order of Administration of Combination Cytokine Therapies Can Decouple Toxicity from Efficacy in Syngeneic Mouse Tumor Models

Saturday, March 24 | 2:30PM - 4:30PM
Workshop: Novel and Sequencing Approaches
Room: Place du Canada

Speaker 4 of 7
Alvaro de Mingo Pulido, Moffitt Cancer Center, USA
TIM-3 Regulates cDC1 Function and Response to Chemotherapy in Breast Cancer

Saturday, March 24 | 2:30PM - 4:30PM
Workshop: Novel and Sequencing Approaches
Room: Place du Canada

Speaker 5 of 7
Jiemiao Hu, University of Texas MD Anderson Cancer Center, USA
Combinational Therapy for Boosting T Cell Transfer to Overcome Heterogeneity and Immune Suppression of Solid Tumors

Saturday, March 24 | 2:30PM - 4:30PM
Workshop: Novel and Sequencing Approaches
Room: Place du Canada

Speaker 6 of 7
Christopher D. Zahm, University of Wisconsin-Madison, USA
TLR Stimulation of Antigen-Presenting Cells Leads to IL-12 Expression that Decreases PD-1 Mediated Regulation

Saturday, March 24 | 2:30PM - 4:30PM
Workshop: Novel and Sequencing Approaches
Room: Place du Canada

Speaker 7 of 7
Hayley S. Ma, Kineta Inc., USA
Combination CD40 Agonist and PD-1 Antagonist Antibody Therapy Enhances Vaccine-Induced T Cell Responses in Non-Immunogenic Cancers

Saturday, March 24 | 4:30PM - 5:00PM
Coffee Available
Room: Square Dorchester/Parc Mont Royal


Saturday, March 24 | 5:00PM - 7:00PM
Incorporating Checkpoint Inhibitors into SOC Chemo- and Radi
otherapy Regimens

Room: Place du Canada

Speaker 1 of 5
* Jane L. Grogan, Arsenal Biosciences, USA

Saturday, March 24 | 5:00PM - 7:00PM
Incorporating Checkpoint Inhibitors into SOC Chemo- and Radi
otherapy Regimens

Room: Place du Canada

Speaker 2 of 5
Ronald Herbst, MedImmune, USA
Combination Therapy for Cancer: Beyond Checkpoint Inhibition

Saturday, March 24 | 5:00PM - 7:00PM
Incorporating Checkpoint Inhibitors into SOC Chemo- and Radi
otherapy Regimens

Room: Place du Canada

Speaker 3 of 5
Andy Minn, University of Pennsylvania, USA
Interferon-Driven Resistance Mechanisms to Immune Checkpoint Blockade Combination Therapy

Saturday, March 24 | 5:00PM - 7:00PM
Incorporating Checkpoint Inhibitors into SOC Chemo- and Radi
otherapy Regimens

Room: Place du Canada

Speaker 4 of 5
Sonia Harnois, Bristol-Myers Squibb, Canada
Short Talk: Relatlimab, An Anti-LAG-3, in Combination with Nivolumab in Melanoma Patients Who Progressed on Anti-PD-1/PD-L1

Saturday, March 24 | 5:00PM - 7:00PM
Incorporating Checkpoint Inhibitors into SOC Chemo- and Radi
otherapy Regimens

Room: Place du Canada

Speaker 5 of 5
Karin Knudson, NCI, National Institutes of Health, USA
Short Talk: An IL-15 Superagonist ALT803in Combination with an Anti-PD-L1

Saturday, March 24 | 7:00PM - 8:00PM
Social Hour with Lite Bites
Room: Square Dorchester/Parc Mont Royal
No registration fees are used to fund alcohol served at this function.

Saturday, March 24 | 7:30PM - 10:00PM
Poster Session 1
Room: Square Dorchester/Parc Mont Royal


Sunday, March 25 | 7:30AM - 8:30AM
Breakfast
Room: Square Dorchester/Parc Mont Royal


Sunday, March 25 | 8:30AM - 11:30AM
Combining Immunotherapy with Tyrosine Kinase and Other Signa
ling Pathway Inhibitors

Room: Place du Canada

Speaker 1 of 6
* Lisa M. Coussens, Oregon Health & Science University, USA
Dynamic Interactions between Myeloid and Lymphoid Cells Regulate Response to Therapy in Solid Tumors

Sunday, March 25 | 8:30AM - 11:30AM
Combining Immunotherapy with Tyrosine Kinase and Other Signa
ling Pathway Inhibitors

Room: Place du Canada

Speaker 2 of 6
Judith A. Varner, University of California, San Diego, USA
Targeting Tissue-Resident Macrophages and Their Progenitors to Suppress Cancer Progression



Sunday, March 25 | 8:30AM - 11:30AM
Combining Immunotherapy with Tyrosine Kinase and Other Signa
ling Pathway Inhibitors

Room: Place du Canada


Coffee Break

Sunday, March 25 | 8:30AM - 11:30AM
Combining Immunotherapy with Tyrosine Kinase and Other Signa
ling Pathway Inhibitors

Room: Place du Canada

Speaker 4 of 6
Chris H. Boshoff, Pfizer Inc., USA
Combining Immune Checkpoint Inhibitors with Targeted Therapies

Sunday, March 25 | 8:30AM - 11:30AM
Combining Immunotherapy with Tyrosine Kinase and Other Signa
ling Pathway Inhibitors

Room: Place du Canada

Speaker 5 of 6
Jane L. Grogan, Arsenal Biosciences, USA
Epigenetic Regulation of Tumor-Associated Myeloid Cell Activity by CBP/EP300 Bromodomain

Sunday, March 25 | 8:30AM - 11:30AM
Combining Immunotherapy with Tyrosine Kinase and Other Signa
ling Pathway Inhibitors

Room: Place du Canada

Speaker 6 of 6
Sabrin Mishel, University of Toronto, Canada
Short Talk: Proximal Signaling through the Innate Immune Inhibitory Receptor Signal Regulatory Protein alpha (SIRPa) in Primary Macrophages

Sunday, March 25 | 11:30AM - 5:00PM
On Own for Lunch


Sunday, March 25 | 11:30AM - 1:00PM
Poster Setup
Room: Square Dorchester/Parc Mont Royal


Sunday, March 25 | 1:00PM - 10:00PM
Poster Viewing
Room: Square Dorchester/Parc Mont Royal


Sunday, March 25 | 4:30PM - 5:00PM
Coffee Available
Room: Square Dorchester/Parc Mont Royal


Sunday, March 25 | 5:00PM - 7:00PM
Sequencing vs. Combinations: Insights from Biomarker and Pre
clinical Studies

Room: Place du Canada

Speaker 1 of 5
* Lisa M. Coussens, Oregon Health & Science University, USA

Sunday, March 25 | 5:00PM - 7:00PM
Sequencing vs. Combinations: Insights from Biomarker and Pre
clinical Studies

Room: Place du Canada

Speaker 2 of 5
Sergio A. Quezada, University College London, UK
Using Preclinical Models and Clinical Samples to Inform Mechanisms and Rational Combinations

Sunday, March 25 | 5:00PM - 7:00PM
Sequencing vs. Combinations: Insights from Biomarker and Pre
clinical Studies

Room: Place du Canada

Speaker 3 of 5
Jo A. Van Ginderachter, VIB-Vrije Universiteit Brussel, Belgium
Tumor-Associated Dendritic Cell Sub-Populations in Cancer Immunity

Sunday, March 25 | 5:00PM - 7:00PM
Sequencing vs. Combinations: Insights from Biomarker and Pre
clinical Studies

Room: Place du Canada

Speaker 4 of 5
Bernard A. Fox, Earle A Chiles Research Institute, USA
Sequencing Checkpoint Therapies

Sunday, March 25 | 5:00PM - 7:00PM
Sequencing vs. Combinations: Insights from Biomarker and Pre
clinical Studies

Room: Place du Canada

Speaker 5 of 5
Ralf Huss, Definiens AG, Germany
Short Talk: Multiplex Immuno-Oncology Panel for Standardized Cancer Profiling of the Immune Status Based on the Spatial and Functional Characterization in the Tumor Microenvironment

Sunday, March 25 | 7:00PM - 8:00PM
Social Hour with Lite Bites
Room: Square Dorchester/Parc Mont Royal
No registration fees are used to fund alcohol served at this function.

Sunday, March 25 | 7:30PM - 10:00PM
Poster Session 2
Room: Square Dorchester/Parc Mont Royal


Monday, March 26 | 7:30AM - 8:30AM
Breakfast
Room: Square Dorchester/Parc Mont Royal


Monday, March 26 | 8:30AM - 11:30AM
Immunotherapy Combinations: Preventing and Managing Resistan
ce to Checkpoint Inhibition and T Cell Exhaustion

Room: Place du Canada

Speaker 1 of 7
* Sergio A. Quezada, University College London, UK

Monday, March 26 | 8:30AM - 11:30AM
Immunotherapy Combinations: Preventing and Managing Resistan
ce to Checkpoint Inhibition and T Cell Exhaustion

Room: Place du Canada

Speaker 2 of 7
Peter S. Hammerman, Novartis Institutes for BioMedical Research, USA
Adaptive Resistance to Immune Checkpoint Blockade

Monday, March 26 | 8:30AM - 11:30AM
Immunotherapy Combinations: Preventing and Managing Resistan
ce to Checkpoint Inhibition and T Cell Exhaustion

Room: Place du Canada

Speaker 3 of 7
Andrea Schietinger, Memorial Sloan Kettering Cancer Center, USA
Molecular and Epigenetic Programs Defining Tumor-Specific T Cell Dysfunction

Monday, March 26 | 8:30AM - 11:30AM
Immunotherapy Combinations: Preventing and Managing Resistan
ce to Checkpoint Inhibition and T Cell Exhaustion

Room: Place du Canada


Coffee Break

Monday, March 26 | 8:30AM - 11:30AM
Immunotherapy Combinations: Preventing and Managing Resistan
ce to Checkpoint Inhibition and T Cell Exhaustion

Room: Place du Canada

Speaker 5 of 7
Gregory Lawrence Beatty, University of Pennsylvania, USA
Strategies for Incorporating CD40 Agonists in Cancer Therapy

Monday, March 26 | 8:30AM - 11:30AM
Immunotherapy Combinations: Preventing and Managing Resistan
ce to Checkpoint Inhibition and T Cell Exhaustion

Room: Place du Canada

Speaker 6 of 7
Yong-Jun Liu, Sanofi, USA
Next Generation of Immunotherapy: Targeting Anti-PD1 Resistance

Monday, March 26 | 8:30AM - 11:30AM
Immunotherapy Combinations: Preventing and Managing Resistan
ce to Checkpoint Inhibition and T Cell Exhaustion

Room: Place du Canada

Speaker 7 of 7
Ramsay Khadeir, Barts Cancer Institute, UK
Short Talk: Pegylated Arginine Deiminase and PD-1/PD-L1 Blockade in the Treatment of ASS1-Deficient Cancers

Monday, March 26 | 11:30AM - 5:00PM
On Own for Lunch


Monday, March 26 | 11:30AM - 1:00PM
Poster Setup
Room: Square Dorchester/Parc Mont Royal


Monday, March 26 | 1:00PM - 10:00PM
Poster Viewing
Room: Square Dorchester/Parc Mont Royal


Monday, March 26 | 4:30PM - 5:00PM
Coffee Available
Room: Square Dorchester/Parc Mont Royal


Monday, March 26 | 5:00PM - 7:00PM
Overcoming T Cell Exclusion and an Immune-Privileged Microen
vironment with Combination Approaches

Room: Place du Canada

Speaker 1 of 5
* Lieping Chen, Yale University, USA

Monday, March 26 | 5:00PM - 7:00PM
Overcoming T Cell Exclusion and an Immune-Privileged Microen
vironment with Combination Approaches

Room: Place du Canada

Speaker 2 of 5
Douglas T. Fearon, Cold Spring Harbor Laboratory, USA
CXCR4 Mediates Immune Privilege in T Cell-Excluded Tumors.

Monday, March 26 | 5:00PM - 7:00PM
Overcoming T Cell Exclusion and an Immune-Privileged Microen
vironment with Combination Approaches

Room: Place du Canada

Speaker 3 of 5
Daniela F. Quail, McGill University, Canada
Macrophage and T Cell Interactions in the Brain Tumor Microenvironment

Monday, March 26 | 5:00PM - 7:00PM
Overcoming T Cell Exclusion and an Immune-Privileged Microen
vironment with Combination Approaches

Room: Place du Canada

Speaker 4 of 5
Hiroyoshi Nishikawa, National Cancer Center Japan, Japan
Control of Tumor-Associated Regulatory T Cells for Effective Cancer Immunotherapy

Monday, March 26 | 5:00PM - 7:00PM
Overcoming T Cell Exclusion and an Immune-Privileged Microen
vironment with Combination Approaches

Room: Place du Canada

Speaker 5 of 5
Casey Ager, University of Texas MD Anderson Cancer Center, USA
Short Talk: Intratumoral Delivery of a Novel STING Agonist Synergizes with Checkpoint Blockade to Regress Multi-Focal Pancreatic Cancer

Monday, March 26 | 7:00PM - 8:00PM
Social Hour with Lite Bites
Room: Square Dorchester/Parc Mont Royal
No registration fees are used to fund alcohol served at this function.

Monday, March 26 | 7:30PM - 10:00PM
Poster Session 3
Room: Square Dorchester/Parc Mont Royal


Tuesday, March 27 | 7:30AM - 8:30AM
Breakfast
Room: Square Dorchester/Parc Mont Royal


Tuesday, March 27 | 8:30AM - 11:30AM
Vaccines, Oncolytic Viruses and Cellular Therapies: Toward C
ombinations

Room: Place du Canada

Speaker 1 of 6
* Mario Sznol, Yale School of Medicine, USA

Tuesday, March 27 | 8:30AM - 11:30AM
Vaccines, Oncolytic Viruses and Cellular Therapies: Toward C
ombinations

Room: Place du Canada

Speaker 2 of 6
Jeffrey Weber, New York University, USA
Clinical Efficacy and Biomarker Analyses in Patients Receiving Adjuvant Checkpoint Blockade for Resected High-Risk Stages III/IV Melanoma

Tuesday, March 27 | 8:30AM - 11:30AM
Vaccines, Oncolytic Viruses and Cellular Therapies: Toward C
ombinations

Room: Place du Canada


Coffee Break

Tuesday, March 27 | 8:30AM - 11:30AM
Vaccines, Oncolytic Viruses and Cellular Therapies: Toward C
ombinations

Room: Place du Canada

Speaker 4 of 6
Olivera J. Finn, University of Pittsburgh School of Medicine, USA
Vaccines for Prevention of Non-Viral Cancers

Tuesday, March 27 | 8:30AM - 11:30AM
Vaccines, Oncolytic Viruses and Cellular Therapies: Toward C
ombinations

Room: Place du Canada

Speaker 5 of 6
Gerald P. Linette, University of Pennsylvania, USA
Melanoma Neoantigen Discovery and Clinical Validation

Tuesday, March 27 | 8:30AM - 11:30AM
Vaccines, Oncolytic Viruses and Cellular Therapies: Toward C
ombinations

Room: Place du Canada

Speaker 6 of 6
Annabelle J. Anandappa, Dana-Farber Cancer Institute, USA
Short Talk: Personal Neoantigen Vaccine for Glioblastoma Stimulates Neoepitope-Specific Intra-Tumoral T Cell Responses

Tuesday, March 27 | 11:30AM - 5:00PM
On Own for Lunch


Tuesday, March 27 | 4:30PM - 5:00PM
Coffee Available
Room: Square Dorchester/Parc Mont Royal


Tuesday, March 27 | 5:00PM - 6:45PM
CTLA-4: Novel Molecules and Approaches to Combinations
Room: Place du Canada

Speaker 1 of 4
* Andrea Schietinger, Memorial Sloan Kettering Cancer Center, USA

Tuesday, March 27 | 5:00PM - 6:45PM
CTLA-4: Novel Molecules and Approaches to Combinations
Room: Place du Canada

Speaker 2 of 4
Spencer C. Wei, Spotlight Therapeutics, USA
Cellular Mechanisms of Combination Checkpoint Blockade

Tuesday, March 27 | 5:00PM - 6:45PM
CTLA-4: Novel Molecules and Approaches to Combinations
Room: Place du Canada

Speaker 3 of 4
Mario Sznol, Yale School of Medicine, USA
Lessons Learned from Anti-CTLA-4 and Anti-PD-1 Combination

Tuesday, March 27 | 5:00PM - 6:45PM
CTLA-4: Novel Molecules and Approaches to Combinations
Room: Place du Canada

Speaker 4 of 4
Alan J. Korman, Vir Biotechnology, Inc., USA
Next-Generation Anti-CTLA-4 Antibodies

Tuesday, March 27 | 6:45PM - 7:00PM
Meeting Wrap-Up: Outcomes and Future Directions
Room: Place du Canada

Speaker 1 of 3
* Chris H. Boshoff, Pfizer Inc., USA

Tuesday, March 27 | 6:45PM - 7:00PM
Meeting Wrap-Up: Outcomes and Future Directions
Room: Place du Canada

Speaker 2 of 3
* Lieping Chen, Yale University, USA

Tuesday, March 27 | 6:45PM - 7:00PM
Meeting Wrap-Up: Outcomes and Future Directions
Room: Place du Canada

Speaker 3 of 3
* Lisa M. Coussens, Oregon Health & Science University, USA

Tuesday, March 27 | 7:00PM - 8:00PM
Social Hour with Lite Bites
Room: Square Dorchester/Parc Mont Royal
No registration fees are used to fund alcohol served at this function.

Tuesday, March 27 | 8:00PM - 11:00PM
Entertainment
Room: Square Dorchester/Parc Mont Royal
Entertainment is not subsidized by conference registration fees nor any U.S. federal government grants. Funding for this expense is provided by other revenue sources.

Tuesday, March 27 | 8:00PM - 11:00PM
Cash Bar
Room: Square Dorchester/Parc Mont Royal


Wednesday, March 28 | 10:24AM - 10:24AM
Departure


*Session Chair.